AU6481301A - Methods for preventing strokes by inducing tolerance to e-selectin - Google Patents

Methods for preventing strokes by inducing tolerance to e-selectin

Info

Publication number
AU6481301A
AU6481301A AU6481301A AU6481301A AU6481301A AU 6481301 A AU6481301 A AU 6481301A AU 6481301 A AU6481301 A AU 6481301A AU 6481301 A AU6481301 A AU 6481301A AU 6481301 A AU6481301 A AU 6481301A
Authority
AU
Australia
Prior art keywords
selectin
methods
mammal
stroke
inducing tolerance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU6481301A
Other languages
English (en)
Inventor
John M Hallenbeck
Hidetaka Takeda
Maria Spatz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Aeronautics and Space Administration NASA
US Department of Health and Human Services
Original Assignee
National Aeronautics and Space Administration NASA
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Aeronautics and Space Administration NASA, US Department of Health and Human Services filed Critical National Aeronautics and Space Administration NASA
Publication of AU6481301A publication Critical patent/AU6481301A/xx
Priority to AU2005235514A priority Critical patent/AU2005235514B2/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/178—Lectin superfamily, e.g. selectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/616—Echinodermata, e.g. starfish, sea cucumbers or sea urchins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU6481301A 2000-05-24 2001-05-23 Methods for preventing strokes by inducing tolerance to e-selectin Pending AU6481301A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2005235514A AU2005235514B2 (en) 2000-05-24 2005-11-22 Pharmaceutical formulations and methods for preventing or treating damage to brain tissue

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20669300P 2000-05-24 2000-05-24
PCT/US2001/016583 WO2001089557A2 (en) 2000-05-24 2001-05-23 Methods for preventing strokes by inducing tolerance to e-selectin

Publications (1)

Publication Number Publication Date
AU6481301A true AU6481301A (en) 2001-12-03

Family

ID=22767527

Family Applications (2)

Application Number Title Priority Date Filing Date
AU6481301A Pending AU6481301A (en) 2000-05-24 2001-05-23 Methods for preventing strokes by inducing tolerance to e-selectin
AU2001264813A Ceased AU2001264813B2 (en) 2000-05-24 2001-05-23 Methods for preventing strokes by inducing tolerance to e-selectin

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001264813A Ceased AU2001264813B2 (en) 2000-05-24 2001-05-23 Methods for preventing strokes by inducing tolerance to e-selectin

Country Status (11)

Country Link
US (2) US7261896B2 (enExample)
EP (2) EP1286686B1 (enExample)
JP (1) JP4986361B2 (enExample)
AT (1) ATE367823T1 (enExample)
AU (2) AU6481301A (enExample)
CA (1) CA2410563C (enExample)
DE (1) DE60129552T2 (enExample)
DK (1) DK1286686T3 (enExample)
ES (1) ES2292594T3 (enExample)
PT (1) PT1286686E (enExample)
WO (1) WO2001089557A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1286686B1 (en) * 2000-05-24 2007-07-25 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES E-selectin for treating or preventing stroke
WO2007028133A2 (en) * 2005-08-30 2007-03-08 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatment and prevention of vascular dementia
US7897575B2 (en) 2000-05-24 2011-03-01 The United States Of America As Represented By The Department Of Health And Human Services Treatment and prevention of vascular dementia
US20070244043A1 (en) * 2005-03-10 2007-10-18 Novavax, Inc. Recombinant E-selectin made in insect cells
US7939078B2 (en) * 2005-07-07 2011-05-10 Codman & Shurtleff Methods of enhancing the immune response to autoantigens in mucosal associated lymphatic tissue
CA2683127A1 (en) * 2006-10-09 2008-04-17 Government Of The United States Of America As Represented By The Secreta Ry Of The Department Of Health And Human Services National Institutes Of Treatment of inflammation, demyelination and neuronal/axonal loss
WO2009038880A1 (en) * 2007-08-01 2009-03-26 Novavax, Inc. Novel e-selectin variant

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3561444A (en) 1968-05-22 1971-02-09 Bio Logics Inc Ultrasonic drug nebulizer
US3703173A (en) 1970-12-31 1972-11-21 Ted A Dixon Nebulizer and tent assembly
US4309406A (en) 1979-07-10 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4309404A (en) 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4704295A (en) 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
US4556552A (en) 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
US4624251A (en) 1984-09-13 1986-11-25 Riker Laboratories, Inc. Apparatus for administering a nebulized substance
US4635627A (en) 1984-09-13 1987-01-13 Riker Laboratories, Inc. Apparatus and method
US5399347A (en) 1987-06-24 1995-03-21 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5081034A (en) * 1988-11-14 1992-01-14 Brigham & Women's Hospital Cloned genes which encode elam-1
AU670024B2 (en) 1989-07-14 1996-07-04 Autoimmune, Inc. Methods of treating or preventing autoimmune uveoretinitis in mammals
EP0506785B1 (en) 1989-12-20 2000-03-15 Autoimmune, Inc. Improved treatment of autoimmune diseases by aerosol administration of auto antigens
EP0782859A1 (en) 1990-03-02 1997-07-09 Autoimmune, Inc. Enhancement of the down-regulation of autoimmune diseases by oral administration of autoantigens
IL97709A (en) 1990-03-30 2005-05-17 Brigham & Womens Hospital Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
IL99754A (en) 1990-10-15 1996-08-04 Autoimmune Inc Pharmaceutical preparation containing autoantib or particle or analogue for the treatment of autoimmune arthritis and multiple sclerosis
US5593698A (en) 1990-10-31 1997-01-14 Autoimmune, Inc. Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
IL99864A (en) 1990-10-31 2000-11-21 Autoimmune Inc Compositions for suppressing transplant rejection in mammals which contain tissue donor derived MHC antigens
EP0627933B1 (en) 1992-02-28 2002-11-27 Autoimmune, Inc. Bystander suppression of autoimmune diseases
BR9306272A (pt) 1992-04-09 1998-06-23 Autoimmune Inc Peptídeo e composiçao farmacêutica
IL106720A (en) 1992-08-17 1998-10-30 Autoimmune Inc The use of antigen bystander in the preparation of compositions for the treatment of neurologically related diseases in mammals and such compositions
IL113303A0 (en) 1994-04-08 1995-07-31 Brigham & Womens Hospital Treatment of autoimmune disease using oral tolerization and/or type I interferon
CA2187345A1 (en) 1994-04-08 1995-10-19 Howard L. Weiner Treatment of autoimmune disease using oral tolerization and/or th2-enhancing cytokines
US5891645A (en) * 1994-06-01 1999-04-06 Alexion Pharmaceuticals, Inc. Porcine E-selectin
GB9507768D0 (en) * 1995-04-13 1995-05-31 Glaxo Group Ltd Method of apparatus
US5948407A (en) * 1997-03-19 1999-09-07 Shire Laboratories Inc. Oral induction of tolerance to parenterally administered non-autologous polypeptides
US5935577A (en) 1998-01-23 1999-08-10 Autoimmune Inc. Treatment of autoimmune disease using tolerization in combination with methotrexate
US20010056073A1 (en) * 1998-07-21 2001-12-27 Ascher Shmulewitz Gene therapy method for revascularizing ischemic tissue
US6974573B2 (en) * 1999-11-01 2005-12-13 Mucovax Holdings, B.V. Antibody production in farm animals
EP1286686B1 (en) * 2000-05-24 2007-07-25 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES E-selectin for treating or preventing stroke
US7897575B2 (en) * 2000-05-24 2011-03-01 The United States Of America As Represented By The Department Of Health And Human Services Treatment and prevention of vascular dementia

Also Published As

Publication number Publication date
WO2001089557A3 (en) 2002-07-04
EP1286686B1 (en) 2007-07-25
CA2410563A1 (en) 2001-11-29
ATE367823T1 (de) 2007-08-15
DE60129552T2 (de) 2008-04-17
AU2001264813B2 (en) 2005-12-08
WO2001089557A2 (en) 2001-11-29
US20070253975A1 (en) 2007-11-01
PT1286686E (pt) 2007-11-07
EP1286686A2 (en) 2003-03-05
DK1286686T3 (da) 2007-11-19
CA2410563C (en) 2013-04-23
ES2292594T3 (es) 2008-03-16
US20040009125A1 (en) 2004-01-15
JP4986361B2 (ja) 2012-07-25
US7261896B2 (en) 2007-08-28
JP2004503471A (ja) 2004-02-05
DE60129552D1 (de) 2007-09-06
EP2295067A1 (en) 2011-03-16

Similar Documents

Publication Publication Date Title
YU30004A (sh) Upotreba flibanserina u lečenju seksualnih poremećaja
AU2036902A (en) Methods and apparatus for stroke patient treatment
BE2012C040I2 (enExample)
TW200509968A (en) Prevention and treatment of synucleinopathic disease
ATE416743T1 (de) Vorrichtung mit energieumwandlungsmitteln zur impotenzbehandlung
AU7186501A (en) Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
MXPA02003724A (es) Uso de un inhibidor selectivo de la recaptacion de noradrenalina combinado con felilalanina o tirosina y composicion.
AU6481301A (en) Methods for preventing strokes by inducing tolerance to e-selectin
EP1297849A4 (en) CURATIVE AGENT FOR OPTICAL AND SIMILAR NERVE DISEASES
AU5340801A (en) Therapeutic compounds and methods
EP1330251A4 (en) POLYTHERAPY FOR THE TREATMENT OF OESTROGENIC SENSITIVE DISEASE
MXPA04005269A (es) Uso de alcanoil-l-carnitina para el tratamiento de disfuncion erectil.
AP2003002867A0 (en) Immune response potentiation
AU4550600A (en) Intervention device
KR200252178Y1 (ko) 안마기
WO2002066037A8 (en) Antiviral method of use
DE202005000335U1 (de) Lichttherapiegerät
WO2001089530A3 (en) Combination therapy for treatment of depression comprising an antidepressant and an ampa receptor potentiator
DE202005001148U1 (de) Trainingsgerät
RU2001110254A (ru) Способ лечения больных с последствиями кранио-цервикальной травмы
ITRN20030008A1 (it) Lettino per trattamento corporeo della persona.
WO2001058407A3 (en) Massaging armchairs
FI20000571A7 (fi) Menetelmä ihmiskehon stimuloimiseksi ultraäänen avulla
ECSP951438A (es) Formas de dosificacion de liberacion controlada de azitromicina
RU2000101949A (ru) Способ лечения ложных суставов